drugset / Trial / NCT04612751
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy with or without carboplatin in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2021-02-02
- Primary completion
- 2026-05-04
- Completion
- 2026-05-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Datopotamab deruxtecan | Monoclonal antibody | — | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Rilvegostomig | Other / unclassified | — | Intravenous |
| Subject | Sabestomig | Monoclonal antibody | — | Intravenous |
| Subject | Volrustomig | Monoclonal antibody | — | Intravenous |